Member Info for OAPK20

Joe the company needs to provide an update regarding where they are with the LDT blood test and progress made with the Chinese partnership and US with CorePath.

.

Best the vote actually happens on the 20th.

In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company will have 180 calendar days, or until October 9, 2023 (the “Compliance Date”), to regain compliance with the MVLS Rule. To regain compliance with the MVLS Rule, the MVLS for the Class A Common Stock must be at least $50 million for a minimum of 10 consecutive business days at any time during this 180-day period. If the Company regains compliance with the MVLS Rule, Nasdaq will provide the Company with written confirmation and will close the matter.

Oh here we go 😁

Widglide.

Just sell up and leave. Sell. Stop posting and leave people to their own choice.

Rollovers ?

No trades. $12.36 to buy. As per independent valuation for Conduit listing.

Also worth remembering

“ While future royalties are contingent on the successful development of AZD1656, the recent clinical trial results are a positive step and Cizzle Biotechnology's royalty rights are not limited to the success of AZD1656 for treating COVID 19. Cizzle Biotechnology's royalty rights also cover the use of AZD1656 for other diseases and AZD1656 has been shown to affect the immune system at sites of damaging inflammation which can be typical in autoimmune disease. Under the full commercial contract entered into, in consideration of the potential future royalty stream from the commercialisation of AZD1656 , Cizzle Biotechnology is to pay GBP135,000 to SGSC.”

Not long until the 7th September.

"The promising results from this trial indicate that AZD1656, a simple oral tablet, has the potential to become a new treatment for COVID-19 – independent of viral mutations – initiating a new wave of therapies for clinicians in meeting this global challenge.”

AZD1656 - also currently under clinical investigation for renal transplant rejection in the UK. The study started 1st January 2020 and the anticipated study completion date was 1st August 2023. (The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit)

If complete then look out for news from Principal Investigator: Kieran McCafferty, M.B., B.Chir, Barts Health NHS Trust; Queen Mary University London, in collaboration with AstraZeneca. Keep and eye on NCT05216172 results tab.

If there are positive results following this extensive trial, aside from the Covid 19 application, how excited will US investors be when Conduit pharmaceuticals lists on the NASDAQ with AZD1656 potentially moving to stage III study and commercialisation.

Makes the timing of the NASDAQ listing interesting in my view. Especially if there is a "partner" or even a "buyer" for AZD1656.

"SGSC is actively engaged in commercial discussions with appropriate global and regional pharmaceutical companies, with the objective of outright sale, partnership in future development or securing funding for the additional clinical studies necessary to get this to market. Ideally AZD1656 would be evaluated in broader non-diabetic patient populations, both hospitalised patients and those at higher risk of hospitalisation due to underlying health conditions. Despite the unknowns around the evolution of the pandemic, SGSC believes that AZD1656 has the potential to generate significant long-term revenue."

Be interesting to see the Conduit share price on listing especially with positive news in the pipeline regarding Renal transplant, Kidney transplant patients with Type 2 diabetes.

If that share price rises and CIZ exercise the put Option to receive £3.25M of shares in Conduit at an issue price of $10 per share what's the likelihood CIZ share price rises accordingly.

Once a magician came to loot a village.

Magician- I will give you 1000 rupees per monkey. Will you catch monkeys for me?

Villagers- Yes! We will. [They felt happy for making easy money.]

[Magician started buying monkeys. After some days the population of monkeys went down. It was difficult for villagers to find monkeys.Villagers stopped catching monkeys and started firming again.]

Magician- I will give 2000 rupees per monkey.

[Again, villagers started catching monkeys. But the supply decreases because it was hard to find monkeys. Some villagers found and got rich. But many of the villagers went to firm again.]

Magician- I need more monkeys. Please find some.

Villagers- We need more money. We want 5,000 per monkey as there are few monkeys left.

[The supply went down, demand went high, so villagers started charging more. The price went high.]

Magician- Okay. I will give you 5,000 per monkey.

Villagers provided some monkeys for 5,000 rupees. There was no monkey left in the jungle.

Now, the demand was in peak. Villagers asked the magician for 10,000 per monkey and they decided to take monkeys from another village.

Again price went high.

Magician played a trick.

He said his assistant to sell all the monkeys he had for 7, 500 to the villagers.

The demand was high.

Villagers wanted to make more money selling monkeys at 10, 000 to the magician.

So, they bought all the monkeys in ignorance from the assistant of the magician.

Now, the villagers had all the monkeys but the magician had left the village with money.

Now, there was no demand as the magician had gone.

The monkeys were just useless for the villagers.

Now, the price for the monkeys was zero.

Demand went down, price went down.

50,000 v 20,000

How are the “customers” doing ?

“There continues to be uncertainty over the timing of commencement of several such anticipated orders which is out of our control. Consequently, revenues and earnings for FY 2023 are now expected to be significantly behind current market expectations: the Board anticipates that revenues for FY 2023 will be not less than GBP2.8M.“

From RNS -

Variation to GBP500,000 Loan Facility

Cizzle Biotechnology, the UK-based diagnostics developer, is pleased to announce that it has conditionally raised gross proceeds of GBP350,000 (before expenses of GBP17,500) by way of the issue of 16,666,667 new Ordinary Shares at 2.1p per share ("Issue Price") with new and existing Investors (the "Subscription").

Use of Proceeds

-- The funds raised from the Subscription will be used, inter alia, to provide working capital for the Company's strategy and to:

o Continue development of a laboratory-developed test ("LDT") accredited service for the early detection of lung cancer.

o Progress the Company's proprietary CIZ1B biomarker blood test through to UKCA, CE marking and/or FDA 510(k) clearance and;

o Commence development of its Point of Care rapid test for use in doctors' offices and pharmacies.

Variation to GBP500,000 Loan Facility

Pursuant to its facility agreement with E3 Fund SP (the "Investor") entered into on 20 September 2022 ("Facility") and amended on 21 April 2023, the Company and the Investor are pleased to announce they have agreed to vary the terms of the Facility to enable the Subscription to proceed at a premium to the fixed repayment price of the Facility of 1.8p per share.

The Facility has been extended until 8 December 2024 and will be drawable in tranches of not less than GBP100,000 as requested by the Company or the Investor. The first drawdown will be made available to the Company following Shareholder Approval at the Company's next General Meeting to allot a further 23,809,524 new Ordinary Shares. Repayment of the Facility is to be by way of issue and allotment of new Ordinary Shares in the capital of the Company at a new fixed price equal to the Issue Price of 2.1p per share ("Facility Shares").

Bottom of page 3. This was 2016 by the way. 7 years ago. You don’t think progress has been made ?

https://eprints.whiterose.ac.uk/107936/1/Coverley_Nov_2016_.pdf

List then announce stage 1

How much progress? How’s everyone’s confidence?

Good partners ?

“The company’s significant expertise in phage display technology, combined with a diverse approach to generating both immune and naïve antibody libraries have contributed to a market leading 99%+ project success rate.“

Commenting, Allan Syms, Executive Chairman, said: “I am delighted that we have contracted with FairJourney Biologics to develop and supply the monoclonal antibodies and reagents required for our ELISA assay and future diagnostic platforms and tests. FairJourney Biologics is a recognised leader in its field and will be an important partner in our strategy to commercialise as quickly as possible our CIZ1B biomarker test for the early-stage detection of lung cancer.

“Since the admission of Cizzle Biotechnology to trading on the London Stock Exchange in May we are already making significant progress and I look forward to providing further updates in due course.”

Commenting, António Parada, Chief Executive Officer, said: “We are excited to collaborate with Cizzle Biotechnology in discovering novel antibodies to be used as promising diagnostic tools. We believe that innovative diagnostic platforms as the CIZ1B biomarker test will be a major step to hinder the progression of lung cancer and improve patient’s prognosis in the long-term.”

#PRD is THE epitome of

The needle in the haystack

In my time, I have dissected many haystacks

Straw by meticulous straw

And identified several needles

that delivered epic returns

But this one ...is

off the scale

I have good reason to say that

That's it🔥

0.1p profit for the sellers. Careful how you spend that £90

Https://www.mining.com/us-department-of-energy-adds-copper-to-critical-minerals-list/

Copper’s now a US critical mineral here’s how that could impact ASX stocks in the US and South America.

Oz investors excited. Nothing here